How can new drug candidates clear R&D hurdles and advance from lab concepts to clinical trials? Seven years after its STAR Market listing, Medicilon delivers a CRO answer: stepping beyond isolated service nodes to build an open, evolving innovation ecosystem that unites original research, translational maturation, capital support, AI enablement, talent development and client collaboration. Together, these stakeholders enable an uninterrupted Target‑to‑IND pathway for new drug discovery.
Foundational Innovation : Partnering with Academic Institutions
Innovative drugs are rooted in fundamental research. Medicilon maintains long‑term partnerships with China Pharmaceutical University, Shanghai University, Putian University and other academic institutions. Through research grants, joint projects and tailored talent programmes, we connect basic science with industrial translation. For academic teams with promising ideas but limited infrastructure, Medicilon drives projects from target identification through IND submission, smoothing the path for early innovation.
Translational Maturation : Working with Leading Experts
Early research outcomes require specialised support to cross the “valley of death”. Launched in 2022, Medicilon Academician Innovative Drug Maturation Center ranks among Pudong’s first Government‑led Open Innovation (GOI) centres. It integrates drug financing, end‑to‑end R&D and licensing services, offering full cycle support for early assets covering R&D, regulatory filing, financing and deal matching. The centre has served over 70 clients and advanced multiple academicians led programmes to secure IND approvals.
Capital Momentum : Linking Investors to Sustain Innovation
Early drug discovery relies on both technical platforms and continuous funding. Medicilon collaborates with financial partners to create a dedicated biotech financing platform, supporting drug development, testing, and commercialization. Its transparent framework also accelerates licensing and transactions for R&D achievements.
AI+CRO Integration : Collaborating with AI-Driven Biotechs
AI is reshaping the drug development paradigm, yet virtually designed molecules require compliant wet‑lab validation to identify viable candidates. Medicilon runs a closed dry and wet workflow: AI predictive modelling paired with regulated experimental validation. Our MAIDD platform supports small molecules, biologics, peptides and small nucleic acids, complemented by an NAMs service platform to lift R&D efficiency.
Medicilon also co‑founded the Zhangjiang AI Drug Discovery Alliance with Zhangjiang Group. We work closely with leading AI drug discovery companies including Insilico Medicine, MindRank and XtalPi, translating their algorithm‑generated molecules into preclinical assets ready for regulatory filing.
Talent Development : Joint University–Industry Cultivation
A resilient innovation ecosystem depends on skilled interdisciplinary researchers. Together with China Pharmaceutical University, Medicilon operates faculty exchanges, joint laboratories, collaborative grant applications and academic symposia to train high‑level drug discovery professionals. We also recruit global experts and maintain structured internal career tracks for technical staff.
Medicilon has donated to China Pharmaceutical University, Fudan University, Shanghai University and Putian University to strengthen pharmaceutical education and discipline development, building a lasting talent base for the industry.
Shared Growth with Global Clients : Taking Innovation Go Worldwide
The ecosystem’s core mission is to bring novel medicines from the lab to patients, across borders. With roughly 29,000 m² of GLP laboratories, nearly 1,100 animal models, and platforms for emerging modalities such as ADC/AOC, small nucleic acids, cyclopeptide, TPD and RIPTAC, Medicilon holds GLP accreditations from NMPA, FDA and OECD. These credentials support regulatory submissions across China, the US, Europe, Australia and beyond. We have served more than 2,000 global clients and supported 691 IND approvals, spanning multinational pharma, emerging biotechs and AI-driven biotechs.
Over seven years, Medicilon has built this interconnected innovation network to advance drug discovery through collaborative growth. Medicilon continues to expand this open ecosystem, bridging academia, capital, technology, talent and industry to move more new drug candidates from Target to IND and onto the global stage.
